Comparative effectiveness and cost-effectiveness of natalizumab and fingolimod in rapidly evolving severe relapsing-remitting multiple sclerosis in the United Kingdom

Journal: J Med Econ

Publication date: 2024

Journal: J Med Econ

Publication Year: 2024

Authors & Co-authors: